AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7560119 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 34
Study 7560119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2376246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure ventilation (INPV) 6 h per day for 5 consecutive days
Number of subjects: 10
Study 2376246 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 10
Study 7372783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous beta-endorphin infusion
Number of subjects: 10
Study 7372783 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 10
Study 31739173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status (s-25(OH)D3)
Number of subjects: 212
Study 31739173 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-overweight status
Number of subjects: 212
Study 31739173 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sun vacations
Number of subjects: 212
Study 30554861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 76
Study 30554861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 27930452 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple CHO + protein (MCP)
Number of subjects: 10
Study 27930452 — intervention group
Group type: COMPARATOR
Intervention: Multiple CHO (MCO)
Number of subjects: 10
Study 26353829 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (1,600 IU/day for <1 year old, 2,400 IU/day for >1 year old)
Number of subjects: 62
Study 26353829 — intervention group
Group type: COMPARATOR
Intervention: Usual intake of vitamin D (400 IU for <1 year old, 600 IU for >1 year old)
Number of subjects: 62
Study 23368915 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 polyunsaturated fatty acids (PUFAs) supplemented parenteral nutrition (PN)
Number of subjects: 60
Study 23368915 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous parenteral nutrition (PN) without ω‐3 PUFAs
Number of subjects: 60
Study 21269649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery with implantation of the CorCap cardiac support device (treatment group)
Number of subjects: 193
Study 21269649 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve surgery alone (control group)
Number of subjects: 193
Study 19149978 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (150 microg/kg orally)
Number of subjects: 240
Study 19149978 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/day for 6 weeks) followed by Ivermectin (150 microg/kg orally)
Number of subjects: 240
Study 17640544 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely revascularization
Number of subjects: 0
Study 17640544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump counterpulsation
Number of subjects: 0
Study 17640544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular assist devices
Number of subjects: 0
Study 17640544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 17640544 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent heart transplantation
Number of subjects: 0
Study 15154636 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol ice balls
Number of subjects: 32
Study 15154636 — intervention group
Group type: COMPARATOR
Intervention: No allopurinol ice balls
Number of subjects: 32
Study 15154636 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol ice balls after initial stomatitis
Number of subjects: 32
Study 11208636 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg twice daily
Number of subjects: 751
Study 11208636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study 9033439 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 21 micrograms twice daily
Number of subjects: 243
Study 9033439 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micrograms twice daily
Number of subjects: 243
Study 9033439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 8331545 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of APD over 4 h
Number of subjects: 20
Study 8331545 — intervention group
Group type: COMPARATOR
Intervention: 60 mg of APD over 24 h
Number of subjects: 20
Study 3579263 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 41
Study 3579263 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-Chloramphenicol
Number of subjects: 41
Study 31278458 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolisation
Number of subjects: 100
Study 31278458 — intervention group
Group type: COMPARATOR
Intervention: Radical excision
Number of subjects: 100
Study 28630396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse lavage (PL)
Number of subjects: 0
Study 28630396 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed drainage (CD)
Number of subjects: 0
Study 28630396 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine lavage (IL)
Number of subjects: 0
Study 28630396 — intervention group
Group type: COMPARATOR
Intervention: Saline lavage (SL)
Number of subjects: 0
Study 24053189 — intervention group
Group type: EXPERIMENTAL
Intervention: New alternating pressure air mattress (APAM) with low friction layer and novel air-cell pressure control
Number of subjects: 0
Study 24053189 — intervention group
Group type: COMPARATOR
Intervention: Control alternating pressure air mattress (APAM)
Number of subjects: 0
Study 23183351 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 0.02% for 5 seconds
Number of subjects: 184
Study 23183351 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 184
Study 20932155 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose doxycycline (SDD)
Number of subjects: 46
Study 20932155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19772521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-targeted mice
Number of subjects: 0
Study 19772521 — intervention group
Group type: EXPERIMENTAL
Intervention: RANKL
Number of subjects: 0
Study 16237386 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol (Estrofem; 2 mg)
Number of subjects: 11
Study 16237386 — intervention group
Group type: COMPARATOR
Intervention: buspirone (Buspar; 5 mg)
Number of subjects: 11
Study 16237386 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 16237386 — intervention group
Group type: EXPERIMENTAL
Intervention: combined buspirone and estradiol
Number of subjects: 11
Study 15504379 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion (600 mg mifepristone and 1 mg gemeprost)
Number of subjects: 1135
Study 15504379 — intervention group
Group type: COMPARATOR
Intervention: Surgical abortion (vacuum aspiration in general anesthesia)
Number of subjects: 1135
Study 15504379 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion
Number of subjects: 1135
Study 15504379 — intervention group
Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 1135
Study 10843450 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 0.5 mg twice daily
Number of subjects: 121
Study 10843450 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 0.5 mg twice daily
Number of subjects: 121
Study 10843450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.1 mg once daily
Number of subjects: 121
Study 9112292 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MIU x 3 per week for 6 months (arm A)
Number of subjects: 116
Study 9112292 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MIU x 3 per week for 3 months and then 3 MIU x 3 per week for 3 months (arm B)
Number of subjects: 116
Study 9112292 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype 1a
Number of subjects: 116
Study 9112292 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype 1b
Number of subjects: 116
Study 9112292 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype 2
Number of subjects: 116
Study 9112292 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype 3
Number of subjects: 116
Study 9112292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained HCV RNA response
Number of subjects: 116
Study 8226457 — intervention group
Group type: EXPERIMENTAL
Intervention: H10/1 protocol (10 repetitions maximum with 1-min rest)
Number of subjects: 9
Study 8226457 — intervention group
Group type: EXPERIMENTAL
Intervention: S10/3 protocol (strength protocol with 10 repetitions maximum and 3-min rest)
Number of subjects: 9
Study 8226457 — intervention group
Group type: EXPERIMENTAL
Intervention: H10/1 protocol
Number of subjects: 9
Study 8226457 — intervention group
Group type: EXPERIMENTAL
Intervention: H5/1 protocol (5 repetitions maximum with 1-min rest)
Number of subjects: 9
Study 8226457 — intervention group
Group type: EXPERIMENTAL
Intervention: H10/1 and H5/1 protocols
Number of subjects: 9
Study 8226457 — intervention group
Group type: EXPERIMENTAL
Intervention: All three protocols in series 1
Number of subjects: 9
Study 8226457 — intervention group
Group type: EXPERIMENTAL
Intervention: HREPs (heavy-resistance exercise protocols)
Number of subjects: 9
Study 8226457 — intervention group
Group type: EXPERIMENTAL
Intervention: HREPs
Number of subjects: 9
Study 3100464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E1 (PGE1) analogue
Number of subjects: 25
Study 3100464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2839813 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine MMU 18006 (10^5, 10^4, or 10^3 plaque-forming units)
Number of subjects: 34
Study 2839813 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine MMU 18006
Number of subjects: 34
Study 29948666 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid management (CFM)
Number of subjects: 70
Study 29948666 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI-guided goal‐directed fluid management (GDFM)
Number of subjects: 70
Study 28629338 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (intermittent exercise, combining moderate and high intensities; 55 minutes duration, 3 times per week)
Number of subjects: 112
Study 28629338 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological care
Number of subjects: 112
Study 26121986 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred ADL intervention
Number of subjects: 280
Study 26121986 — intervention group
Group type: COMPARATOR
Intervention: Usual ADL intervention
Number of subjects: 280
Study 23763469 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental vignette
Number of subjects: 90
Study 23763469 — intervention group
Group type: COMPARATOR
Intervention: Control vignette
Number of subjects: 90
Study 21570291 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral patella taping
Number of subjects: 13
Study 21570291 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral bracing
Number of subjects: 13
Study 21570291 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 13
Study 19483109 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2-high asthma
Number of subjects: 42
Study 19483109 — intervention group
Group type: COMPARATOR
Intervention: Th2-low asthma
Number of subjects: 42
Study 19483109 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 42
Study 16908478 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Responsiveness Scale (SRS)
Number of subjects: 73
Study 16908478 — intervention group
Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Composite
Number of subjects: 73
Study 16908478 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism Diagnostic Interview‐Revised
Number of subjects: 73
Study 14558397 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 20% 5-aminolevulinic acid (5-ALA) followed by 595 nm pulsed dye laser (PDL) irradiation
Number of subjects: 10
Study 14558397 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL) treatment alone or untreated lesions
Number of subjects: 10
Study 10674589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollerball endometrial ablation
Number of subjects: 39
Study 9060894 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 98
Study 9060894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 8403573 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 U/kg (G5)
Number of subjects: 107
Study 3804884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g intravenously every 12 h for mean duration 8.7 days)
Number of subjects: 30
Study 3804884 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (1.5 g intravenously every 6 h for mean duration 8.2 days)
Number of subjects: 30
Study 30839013 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO, n = 35, 2 g day‐1 eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 108
Study 30839013 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 108
Study 30839013 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FLO, n = 39, 2.5 g day‐1 α‐linolenic acid)
Number of subjects: 108
Study 30839013 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FLO)
Number of subjects: 108
Study 30839013 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (CO, n = 34)
Number of subjects: 108
Study 28335886 — intervention group
Group type: EXPERIMENTAL
Intervention: OxCapRT (oxaliplatin 85 mg/m2 day 1, 15, 29; capecitabine 625 mg/m2 bd on days of radiotherapy)
Number of subjects: 85
Study 28335886 — intervention group
Group type: COMPARATOR
Intervention: CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 day 1, 8, 15, 22, 29)
Number of subjects: 85
Study 26096029 — intervention group
Group type: EXPERIMENTAL
Intervention: eSET
Number of subjects: 65
Study 26096029 — intervention group
Group type: COMPARATOR
Intervention: eDET
Number of subjects: 65
Study 25607706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream
Number of subjects: 0
Study 25607706 — intervention group
Group type: COMPARATOR
Intervention: Azelaic acid 15% gel
Number of subjects: 0
Study 23066119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644
Study 23066119 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 IU vitamin D(3)
Number of subjects: 644
Study 23066119 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 IU vitamin D(3)
Number of subjects: 644
Study 19208350 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 1 month (increased to 40 mg/day at day 15)
Number of subjects: 59
Study 19208350 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin with beta-adrenergic blockers
Number of subjects: 59
Study 19208350 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin without beta-adrenergic blockers
Number of subjects: 59
Study 19208350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17554116 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprodisate
Number of subjects: 183
Study 17554116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 15168839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Episode
Number of subjects: 152
Study 15168839 — intervention group
Group type: COMPARATOR
Intervention: Manic Episode
Number of subjects: 152
Study 12063011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala-9Val polymorphism in SOD2 gene
Number of subjects: 80
Study 12063011 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with no clinically detectable reaction)
Number of subjects: 80
Study 9469328 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 551
Study 9469328 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 551
Study 9469328 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (MA) 160 mg
Number of subjects: 551
Study 9469328 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 0.5 mg
Number of subjects: 551
Study 7818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with precocious coronary heart disease (CHD)
Number of subjects: 107
Study 7818160 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives of patients with CHD
Number of subjects: 107
Study 7818160 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 107
Study 7818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD
Number of subjects: 107
Study 7818160 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives of patients with CAD
Number of subjects: 107
Study 7818160 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives of hyperlipidemic patients
Number of subjects: 107
Study 7818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Families studied
Number of subjects: 107
Study 2120639 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg h‐1 intra‐arterial rt‐PA
Number of subjects: 17
Study 2120639 — intervention group
Group type: COMPARATOR
Intervention: 5000 units h‐1 Sk and 250 units h‐1 heparin intra‐arterially
Number of subjects: 17
Study 224083 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride dentifrice in a silica gel base
Number of subjects: 1339
Study 224083 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride dentifrice in a calcium pyrophosphate base
Number of subjects: 1339
Study 224083 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoride control dentifrice
Number of subjects: 1339
Study 29967948 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB) with 4 mg/kg sugammadex at post-tetanic count (PTC) of 2
Number of subjects: 108
Study 29967948 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (NMB) with 2 mg/kg sugammadex at a train-of-four (TOF) count of 1 or 2
Number of subjects: 108
Study 29967948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Deep NMB and Moderate NMB)
Number of subjects: 108
Study 28854592 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction intervention followed by IVF treatment; 12 weeks of low calorie liquid formula diet (LCD) of 880 kcal/day followed by weight stabilization for 2-5 weeks.
Number of subjects: 317
Study 28854592 — intervention group
Group type: COMPARATOR
Intervention: IVF treatment only.
Number of subjects: 317
Study 26014321 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR maneuver
Number of subjects: 35
Study 26014321 — intervention group
Group type: COMPARATOR
Intervention: ART method
Number of subjects: 35
Study 23897918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal tube
Number of subjects: 363
Study 23897918 — intervention group
Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 363
Study 21157393 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercises (prone bridge [PB] and superman [SM])
Number of subjects: 10
Study 21157393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercises (back squat, front squat [FS], and military press)
Number of subjects: 10
Study 21157393 — intervention group
Group type: EXPERIMENTAL
Intervention: Front squat (FS)
Number of subjects: 10
Study 21157393 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercises (PB)
Number of subjects: 10
Study 19554082 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-6
Number of subjects: 5680
Study 19554082 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 5680
Study 19554082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 5680
Study 19554082 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 5680
Study 17719320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 59
Study 17719320 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 59
Study 15507794 — intervention group
Group type: EXPERIMENTAL
Intervention: assess/advise/treat group
Number of subjects: 102
Study 15507794 — intervention group
Group type: COMPARATOR
Intervention: assess/advise/wait group
Number of subjects: 102
Study 11480656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral insomnia therapy (CBT)
Number of subjects: 75
Study 11480656 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation training
Number of subjects: 75
Study 11480656 — intervention group
Group type: COMPARATOR
Intervention: Sham behavioral intervention
Number of subjects: 75
Study 9926274 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 8 mg
Number of subjects: 25
Study 9926274 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg
Number of subjects: 25
Study 9926274 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol 10 mg
Number of subjects: 25
Study 9926274 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 8059623 — intervention group
Group type: COMPARATOR
Intervention: Control patients attending the UNC Family Practice Center for a routine Papanicolaou smear
Number of subjects: 373
Study 8059623 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions made to inform control patients of the risk of HPV and need for closer follow-up
Number of subjects: 373
Study 3058043 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin 2 (IL2) administered intravenously at doses of 1 x 10(4), 3.3 ‐ 5 x 10(4), 1 x 10(5), 3.3‐5 x 10(5), 1 x 10(6) and 3.3 x 10(6) U/day
Number of subjects: 40
Study 3058043 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin 2 (IL2) administered subcutaneously at a dose of 1 x 10(6) U/day for 5 days
Number of subjects: 40
Study 31378111 — intervention group
Group type: EXPERIMENTAL
Intervention: Group rational emotive behavioural intervention
Number of subjects: 36
Study 31378111 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 29236529 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings on red backgrounds
Number of subjects: 544
Study 29236529 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings on white backgrounds
Number of subjects: 544